EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection

Kari Ann Shirey, Alessio Romerio, Mohammed Monsoor Shaik, David S Leake, Charys Palmer, Natalia Skupinska, Jules Paton iD, Grisha Pirianov, Jorge Cg Blanco, Stefanie N Vogel, Francesco Peri iD

Innate Immunity · 2025-01 · 31

DOI: 10.1177/17534259241313201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innate Immunity, online erschienen am 03.03.2025. Verfasst von Kari Ann Shirey und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Lymphocyte Antigen 96, Orthomyxoviridae Infections, Acute Lung Injury. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, British Heart Foundation, EU-Next generation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Acute Lung Injuries (ALI) are a severe consequence of influenza-induced cytokine storm that can cause respiratory failure and death. It has been demonstrated that Toll-like Receptor 4 (TLR4) is involved in cytokine storm and that TLR4 −/− mice are protected against ALI. Therefore, TLR4 is a prime target for protection against ALI. FP12 is a known TLR4 antagonist that reduces TLR4-dependent immune activation and it is a promising lead compound for the treatment of innate immunity related pathologies.

Objectives

We present here the preclinical development of FP12 as an anti-inflammatory lead compound acting on influenza-induced ALI.

Methods

In vitro: We pre-treated THP-1 cells with FP12 (10 μM) for 0.5 h, then exposed to LPS (100 ng/ml) for 0 to 16 h. In some experiments, cells were simultaneously incubated with FP12 and LPS, or FP12 was added 30 min after LPS. Cytokine levels were measured by Western blot and ELISA assays. In vivo: WT C57BL/6J mice were infected with mouse-adapted influenza virus (PR8). Two days after infection, mice received either vehicle, FP7 (200 µg/mouse), or FP12 (200 µg/mouse) once daily (Day 2 to Day 6). Mice were monitored daily for survival for 14 days. Data were collected through histological staining, qRT-PCR, and ELISA assay.

Results

FP12 treatment inhibited both LPS- and HMGB1-induced TLR4 intracellular pathways (MyD88 and TRIF) leading to significantly reduced levels of a variety of proinflammatory cytokines including Type I interferon (IFN-β), highlighting its effectiveness in controlling proinflammatory protein production and reducing inflammation. FP12 protected mice therapeutically from influenza virus-induced lethality and reduced both cytokine gene expression and High Mobility Group Box 1 (HMGB1) levels in the lungs as well as ALI.

Conclusion

FP12 can antagonize TLR4 activation in vitro and protects mice from severe influenza infection, most likely by reducing the TLR4-dependent cytokine storm mediated by danger-associated molecular patterns (DAMPs).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4Lymphocyte Antigen 96Orthomyxoviridae InfectionsAcute Lung InjuryInfluenza, HumanAnti-Inflammatory AgentsAnimalsHMGB1 ProteinHumansMiceMice, Inbred C57BLSignal TransductionCell LineLipopolysaccharidesCytokinesMice, Knockout

Stichwörter der Autor:innen

ALIDrug discoveryHMGB1TLR4influenza

Substanzen

Toll-Like Receptor 4HMGB1 ProteinLymphocyte Antigen 96LipopolysaccharidesCytokinesTlr4 protein, mouseAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of Maryland, School of Medicine, Baltimore, Maryland, USA.
  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milano, Italy.
  • School of Biological Sciences, Health and Life Sciences Building, University of Reading, Reading, Berkshire, UK.
  • School of Life Sciences, Anglia Ruskin University, Cambridge, UK.
  • Sigmovir Biosystems Inc., Rockville, MD, USA.

ORCID-Profile: Jules Paton, Francesco Peri

Förderung

  • NCATS NIH HHS
  • British Heart Foundation
  • EU-Next generation
  • university of maryland institute for clinical and translational research
  • British Heart Foundation Centre of Regenerative Medicine

Zitieren

APA

Shirey, K. A., Romerio, A., Shaik, M. M., Leake, D. S., Palmer, C., Skupinska, N., Paton, J., Pirianov, G., Blanco, J. C., Vogel, S. N., & Peri, F. (2025). Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. Innate Immunity, 31. https://doi.org/10.1177/17534259241313201

Vancouver

Shirey KA, Romerio A, Shaik MM, Leake DS, Palmer C, Skupinska N, et al. Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection. Innate Immunity. 2025;31. doi:10.1177/17534259241313201

BibTeX
@article{Shirey2025,
  author = {Shirey, Kari Ann and Romerio, Alessio and Shaik, Mohammed Monsoor and Leake, David S and Palmer, Charys and Skupinska, Natalia and Paton, Jules and Pirianov, Grisha and Blanco, Jorge Cg and Vogel, Stefanie N and Peri, Francesco},
  title = {Preclinical development of the TLR4 antagonist FP12 as a drug lead targeting the HMGB1/MD-2/TLR4 axis in lethal influenza infection},
  journal = {Innate Immunity},
  year = {2025},
  volume = {31},
  doi = {10.1177/17534259241313201}
}
Kostenlos starten →